Clinical Trial Approval For The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines

TAIZHOU, China, Dec. 19, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the 'Company', together with its subsidiaries, the 'Group') is ...

Related Keywords

China ,Taizhou ,Jiangsu ,Philippines ,Hong Kong ,The Philippines , ,Stock Exchange Of Hong Kong ,Jiangsu Recbio Technology Co Ltd ,Drug Administration Of The Philippines ,Prnewswire Jiangsu Recbio Technology Co Ltd ,Drug Administration ,Press Release ,Stock Exchange ,Hong Kong Limited ,